# XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer

> **NCT04825288** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **XBiotech, Inc.** · enrollment: 76 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** XB2001 or Placebo

## Key facts

- **NCT ID:** NCT04825288
- **Lead sponsor:** XBiotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-27
- **Primary completion:** 2023-10-26
- **Final completion:** 2025-06-10
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04825288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04825288, "XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04825288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*